5.01
6.53%
-0.35
Genenta Science Spa Adr stock is traded at $5.01, with a volume of 4,738.
It is down -6.53% in the last 24 hours and up +6.60% over the past month.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
See More
Previous Close:
$5.36
Open:
$5.35
24h Volume:
4,738
Relative Volume:
0.36
Market Cap:
$91.63M
Revenue:
-
Net Income/Loss:
$-12.63M
P/E Ratio:
-10.42
EPS:
-0.4808
Net Cash Flow:
$-12.18M
1W Performance:
-2.34%
1M Performance:
+6.60%
6M Performance:
+55.35%
1Y Performance:
+0.20%
Genenta Science Spa Adr Stock (GNTA) Company Profile
Name
Genenta Science Spa Adr
Sector
Industry
Phone
-
Address
-
Compare GNTA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
GNTA
Genenta Science Spa Adr
|
5.01 | 91.63M | 0 | -12.63M | -12.18M | -0.6942 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-29-23 | Resumed | ROTH MKM | Buy |
Jul-25-22 | Initiated | H.C. Wainwright | Buy |
Jan-13-22 | Initiated | Maxim Group | Buy |
Genenta Science Spa Adr Stock (GNTA) Latest News
Genenta Science Updates ATM Sales Agreement with New Agent - TipRanks
Genenta Science SPA (ADR) trading resumes - TipRanks
Genenta Science SPA (ADR) trading halted, volatility trading pause - TipRanks
3 US Penny Stocks With Market Caps Over $30M To Consider - Yahoo Finance
Genenta Science CEO to present at U.S. Senate meeting - TipRanks
Genenta Science receives Buy rating amid trial approval - Investing.com
Company’s Banking Stock: Dissecting a 38.98% Quarterly Revenue Decline Amid Growth - The InvestChronicle
DHR Stock Quote Price and Forecast - CNN
Danaher (DHR) Stock Price, News & Analysis - MarketBeat
Genenta Science Spa Adr Stock (GNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):